Donor immune cells take on tough T-Cell cancers in new trial
NCT ID NCT06514794
First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe out cancer cells completely, including those too few to detect with standard tests. Participants must be at least 6 months old and in fairly good health aside from their cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19390, United States
Contact Email: •••••@•••••
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Email: •••••@•••••
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact Email: •••••@•••••
Contact
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
Contact
-
H. Lee Moffitt Cancer Center and Research Institute Hospital
RECRUITINGTampa, Florida, 33612, United States
Contact Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Oncology Hematology Care
RECRUITINGCincinnati, Ohio, 45226, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peter Mac Callum Cancer Institute
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Email: •••••@•••••
Contact
Contact
-
Royal Children's Melbourne
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Email: •••••@•••••
-
Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sarah Cannon, Virginia Oncology Associates
RECRUITINGNorfolk, Virginia, 23502, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact
-
TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
Contact
-
Washington University Saint Louis
RECRUITINGSt Louis, Missouri, 63108, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WU-CART-007 (a type of CAR-T cell therapy made from donor cells)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat T-cell leukemia or lymphoma, potentially leading to long-term remission.
What could go wrong
This is an early-phase trial with only 125 participants, so results may not apply to everyone. CAR-T therapies can cause serious side effects like cytokine release syndrome or nervous system problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.